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Abstract
Monoclonal antibodies (MoAbs) alone or in the combination of conventional therapies
have been used in the treatment of many benign or malign diseases. In the transplanta‐
tion setting, Moabs have been generally applied as a part of conditioning regimen in the
aims of the prevention of graft versus host disease and/or graft failure or treatment of un‐
derlying hematologic disease. The most frequent used moAbs for this purpose are rituxi‐
mab, alemtuzumab, Gemtuzumab Ozogamicin or radioimmunoconjugates. In this
chapter, we discussed the role of moAbs use in the conditioning regimens of allogeneic or
autologous stem cell transplantation.
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1. Introduction
Monoclonal antibodies (MoAbs) to treat a variety of benign and malignant diseases are used
alone or in combination with conventional therapies. The use of MoAbs in autologous and
allogeneic hematopoietic stem cell transplant (allo-HSCT) is subject to the following conditions
for:
1. In vivo purging of graft and as a part of the conditioning regimens in the autologous or
allogeneic HSCTs, and/or
2. Prevention or treatment of graft versus host disease (GvHD) developed after allo-HSCT.
The goals of the use of the MoAbs for in vivo purging of graft and/or as a part of conditioning
regimens in autologous or allogeneic HSCTs are to obtain tumor-free stem cells, to reduce the
recurrence, and to provide the resulting increase in the efficacy of transplantation on the
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underlying disease and the cure rate. Additionally, MoAbs in allo-HSCTs prevent the graft
rejection and/or reduce the frequency and severity of GvHD. More frequent used MoAbs in
the transplantation are: Rituximab, Radioimmunotherapeutics (RITs), Alemtuzumab, and
Gemtuzumab Ozogamisin.
2. Rituximab
Rituximab, the chimeric anti-CD20MoAb is mostly used to treat a broad variety of B-cell non-
Hodgkin’s lymphomas (NHL). Rituximab shows direct activity or complement-mediated
cytotoxicity and antibody-dependent cytotoxicity. There are numerous studies on the use of
conditioning regimens in autologous and allogeneic HSCTs settings.
The first study was reported by Flinn et al. [1] including 25 patients with a variety of NHL (11
follicular lymphoma, 7 mantle cell lymphoma, 5 chronic lymphocytic leukemia or small
lymphocytic leukemia, 1 lymphoblastic lymphoma, and 1 marginal zone lymphoma). In this
study rituximab was used for in vivo purging during the stem cell mobilization with cyclo‐
phosphamide (Cy) and also added in the myeloablative (MA) conditioning regimen including
mostly Cy plus total body irradiation (TBI) and a further dose given after the engraftment. As
a result, rituximab was well tolerated, engraftment was fast, and temporary neutropenia
developed in the mean of 99.5 days in six patients but clinically significant infection was not
reported.
Following study on the addition of rituximab for the conditioning regimen in autologous HSCT
has been published by Flohr et al. [2]. In this phase II study, 27 patients with a variety of B-cell
NHL in both the first day of the stem cell mobilization with chemotherapy and in the condi‐
tioning regimen,-10 and -3 days at the dose of 375 mg/square meter (sqm) rituximab have been
used. The overall response rate has been reported as 96%. In the median follow-up of 16
months, disease free survival (DFS) and overall survival (OS) have been estimated as 77% and
95%, respectively. Another study of Khouri et al. [3] have evaluated the efficacy of rituximab
use in the stem cell mobilization and after the transplantation in a total of 67 patients with
diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Rituximab (375 mg/
sqm) was infused 1 day before chemotherapy and again administered 7 days after chemo‐
therapy at 1000 mg/sqm. In addition, rituximab has been given to the patients on the first and
eighth day of 1000 mg/sqm dose following the high-dose BEAM conditioning regimen for
autologous HSCT. The results were retrospectively compared with those of a historical control
group (n=30 patients) receiving the same preparative regimen without rituximab. Although
neutrophil engraftment in the rituximab arm was late in a statistically significant proportion
(median 10 days vs.11 days, p <0.05), similar incidence of infection has been shown in the
patients who received rituximab compared with the control arm. In the median 20 months of
follow-up, they reported that the possibilities of progression-free survival (PFS) and OS
significantly prolonged in rituximab arm (PFS: 43% versus 67%, p = 0.004; OS: 53% versus 80%,
p = 0.002). In a multicenter study from 10 centers associated with the Italian group, the Gruppo
ItalianoTerapie Innovative nei Linfomi, when retrospectively compared the high-dose therapies
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with and without rituximab in the patients with DLBCL and FL undergoing autologous HSCT,
either as salvage or as first-line therapy for high-risk presentation, rituximab was administered
in four doses during the high-dose therapy immediately before peripheral blood collection to
exploit the drug’s in vivo purging effect, and two additional doses were usually used after
autologous-HSCT. They found the similar response rate and early transplant-related mortality
between rituximab (+) and (-), but the 5-year projected PFS and OS were better in those with
rituximab (+) (p<0.0001) [4].
Hick et al. have also evaluated the use of rituximab in 23 patients with relapsed FL during the
mobilization of stem cells for in vivo purging and during the 8th and 24th week after autolo‐
gous HSCT for a four-week maintenance treatment protocol [5]. This study showed that
rituximab provided permanent molecular remission in 77% of the patients associated with
significantly prolonged PFS versus those with continued polymerase chain reaction PCR
positivity.
Many single-arm phase II studies including small number of patients have been reported that
the addition of rituximab especially reduced intensity conditioning (RIC) regimens in alloge‐
neic HSCT settings reduced the incidence of acute or chronic GvHD and non-relapse mortality
(NRM) [7-11]. In these studies, rituximab has led to an increase of serious infections due to
long-term cytopenias and prolonged hypogammaglobulinemia.
Ultimately, there is no consensus regarding the dosage and scheme of rituximab use as a part
of conditioning regimen for autologous and allogeneic HSCT in these studies. In addition, it
is also not sufficient in randomized controlled trials demonstrating the superiority of adding
rituximab. Therefore, prospective multicenter randomized trials aiming to determinate the
exact role of rituximab for in vivo purging and/or as a part of conditioning regimens should
be made in lymphoma patients.
3. Radioimmunotherapeutics
Radioimmunotherapeutics (RITs) uses monoclonal antibodies directed against specific tumor
antigens labeled with a particle emitting radioisotope to deliver radiation directly to the tumor.
This type of treatment gives a high dose of radiation to tumor tissue and protects uninvolved
tissues and organs [12-13]. Labeled antibodies to the antigen over-expression in the target
tissue with radioactive substances specifically bind. For this purpose beta- particles are the
most frequently used: Radioactive particles connected the MoAb slowly give out its radiation
and kill the other nearby cells. This is called as cross fire. They give high tissue distribution
with high nucleotides in the target tissue and homogeneous energy and provide the myeloa‐
blation or affect the large tumor mass. To achieve a favorable biodistribution of a radiolabeled
monoclonal antibody, an ideal antigen would be expressed homogeneously on the tumor cell
surface and would lack expression on normal cells. Lacking such an antigen, methods to target
lineage-specific hematopoietic antigens, such as CD20, CD33, and CD45, have been success‐
fully developed in the autologous and allogeneic-HSCT setting.
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Currently there are two RITs in clinical use for indolent NHL [14]: Yttrium-90 ibritumomab
tiuxetan (90Y-IT) (Zevalin) and iodine-131 tositumomab (131I-T) (Bexxar). There are studies on
the use of high or standard doses as a part of the conditioning regimen for the transplantation.
3.1. High-dose RITs
Studies are generally on the use of single or combined with chemotherapy in the conditioning
regimen for autologous-HSCT. In the first study, Press et al. conducted the phase I study in 43
relapsed B-cell lymphoma patients, and the administration of anti-CD20 and anti-CD37
antibodies labeled 131I-T alone in the conditioning regimen was to evaluate the toxicity and
efficacy (15). The maximum tolerated dose was 27.25 Gy. However, researches have shown
that patients administered more than this dose had cardio-toxic effects. In addition, the
biodistribution of the antibodies in the patients with the large spleen size and a large tumor
mass were emphasized not to be good in the study. The overall response rate of 95% with high-
dose RIT (84% complete response and 11% partial response) and tumor response were
calculated as the median of 11 months. Subsequently, the same researchers have made a phase
II study with anti-CD20 labeled 131I-T in 25 patients with relapse NHL [16]. In this study, they
have reported that PFS was 62% and 93% of OS with the median 2-year follow-up. Similarly,
Liu et al. found a median PFS of 42% and 68% of OS in median 42-month follow-up [17]. This
was followed by similar studies regarding the use of the high-dose RITs. However, due to the
gamma radiation emitted by 131I-T most subsequent studies had been conducted with 90Y-IT,
a pure beta emitter [18-21]. There was no need to prolong strict patient isolation and contact
alert in 90Y-IT in contrast to131I-T. Besides, disease statuses prior to the transplantations in those
studies were also variable. Although the use of high-dose RIT was planned for the patients
unable to tolerate high-dose treatment, the majority of patients in the studies was under 60
years of age and had chemosensitive relapses. Additionally, there are no prospective studies to
prove RITs’ superiority to chemotherapy and/or radiotherapy. Furthermore, this treatment
should be administered in specialized centers.
3.2. Standard-dose RITs
To overcome the problems related to the safe yield of high-dose RITs, the efficacies of standard-
dose RITs combined with chemotherapy in preparative regimens of the transplantation have
been assessed in the following studies. The results in several single-arm studies not including
control group were impressive. In a randomized trial, the Blood and Marrow Transplant
Clinical Trials Clinical Trials Network (BMT-CTN) 0401 in which 131I-T-BEAM or Rituximab-
BEAM were given to the patients with chemosensitive relapse of DLBCL [22], disease control
and survival effects of RIT could not have been shown. A randomized study compared 90Y-IT-
BEAM with BEAM alone in recurrent B cell NHL was closed early by reason of the slow patient
recruitment. As their evaluation with a small number of cases, it was the first randomized
study that proved that higher DFS and OS were in the RIT arm. Nevertheless, the published
studies do not support the routine use of standard-dose RITs in DLBCL.
Some studies in chemorefractory DLBCL patients who underwent autologous-HSCT condi‐
tioned by standard-dose RIT have been reported as two or three year PFS and OS 39%–63%
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and 55%–67%, respectively [23-26]. In the European Mantle Cell Network MCL-3 study 90Y-IT
was given to patients younger than 66 years one week prior to BEAM or BEAC (Carmustine,
Etoposide, Cytarabine and Cyclophosphamide) conditioning regimen [27]. When compared
with the results of the MCL-2 study, they concluded that there was no benefit in the patients
undergoing autologous-HSCTas a first-line intensification treatment.
In allogeneic HSCT, RIT has generally been added to the RIC regimens in the refractory NHL
patients. One of the first studies where Shimoni et al. gave 90Y-IT with fludarabine-based
conditioning regimens to 12 patients with chemorefractory CD20+ NHL demonstrated the safety
of RIT [28]. Subsequently, several studies related to adding RITs to the conditioning regimen
have been published [29,30]. Although allogeneic HSCTs made by adding RITs to RIC regimes
have reliability in these studies, it has not been shown to be superior to the transplantations
with RIC regimens not including RIT yet.
There are some studies related to the adding of RITs to the preparative regimens in acute
leukemia and myelodysplastic syndrome (MDS) as well. Initially, 131I-labeled M195, the mouse
Moabs of lintuzumab (reactive with CD33) was used in 10 patients with relapsed or refractory
acute myeloid leukemia in a phase I study from the Memorial Sloan Kettering Cancer Center
[31]. Subsequently, 131I-labeled anti-CD33 MoAbs were added to standard myeloablative
regimen in 31 patients with refractory or relapsed AML (n=16), accelerated or blastic phase
chronic myeloid leukemia (CML) (n=14) or advanced myelodysplastic syndrome (MDS) (n=1)
underwent allogeneic HSCT from their related donor [32]. The median survival was calculated
as 4.9 months (range 0.3–90+ months). Three patients with relapsed AML remain in complete
remission more than 5 years.
Based on the feasibility of MoAbs, investigators have focused on the CD45, the other antigen.
The CD45 antigen, common leukocyte antigen, is expressed on the surface of virtually all
hematopoietic cells, except mature red cells and platelets. In addition, CD45 expression has
been detected in 85% to 90% of AML and ALL, and the antigen does not internalize after the
antibody binding. In a phase I study conducted by the Fred Hutchinson Cancer Center, RIT
with 131I-anti-CD45 has been implanted one week prior to the conditioning regimen including
Cy-TBI in AML beyond the first complete remission (CR), acute lymphoblastic leukemia, and
MDS-excess blast [33]. The patients of this study have undergone allogeneic HSCT from their
human leukocyte antigen (HLA) -identical relative donors or autologous HSCT. This first
study has shown that the radiation with acceptable toxicity should be given to the bone marrow
and spleen. Subsequently RIT with 131I-anti-CD45 has been added to the conditioning regimen
with busulfan (Bu) plus Cy (BuCy) in the patients with the first CR AML [34]. Three-year non-
relapse mortality and disease-free survival in this study was calculated at 21% and 61%,
respectively. They have reported that the results were comparable by the International Bone
Marrow Transplantation Registry (IBMTR) data using only BuCy in allogeneic HSCT.
Similarly Pagel et al. added the RIT to the RIC regimens in elderly patients with advanced stage
or high risk AML and showed the reliability of RIT in a phase I study [35]. Same researches
used the 131I-anti CD45 targeted radiotherapy in combination with Fludarabine plus 2 Gy TBI
in younger patients (age 16 to 50 years) with advanced AML or high-risk MDS who underwent
allogeneic HSCT [36]. They aimed to define the maximum tolerated dose (MTD) of radiola‐
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beled anti-CD45 antibody in addition to non-myeloablative conditioning regimes and to create
better antitumor control with minimal toxicity in comparison with standard myeloablative
regimens. Their study suggested that a maximum dose of 28 Gy could be delivered to the liver
and the arbitrary limit of 43 Gy to the marrow might be unnecessarily conservative. Conjuga‐
tion of anti-CD45 antibody with alternative radioisotopes including 90Y is currently explored
in clinical trials.
Another attempt in the studies was the use of anti-CD66 moAbs in leukemic patients. But
leukemic blasts do not express CD66. Therefore, the anti-leukemic effect of CD66 RIT depends
on “crossfire” from the beta-particles emitted by 188-Rhenium (Re). 188Re-labeled anti-CD66
moAbs were used as a part of the standard myeloablative conditioning regimen including total
body irradiation (12 Gy) (n = 30) or busulfan (n = 27) and high-dose cyclophosphamide +/-
thiotepa prior to allogeneic or autologous HSCT in 57 patients with high-risk AML or MDS
[37]. In median 26 months follow-ups, disease-free survival were 64% for 44 patients in the
first or second CR or in very good partial remission (less than 15% blasts in the marrow at
transplantation) and only 8% for those with more than 15% blasts in the marrow at transplan‐
tation. Likewise, targeted marrow irradiation with 188Re-anti-CD66 moAbs were used in 20
patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or advanced
CML prior to allogeneic HSCT [38]. With a median follow-up of 54 months (range 23–81)
overall and disease-free survival were 29% (95%-CI 14–58) and 25% (95%-CI 12–53), respec‐
tively. Subsequently, conjugation of anti-CD66 with 188Re or 90Y were added to a reduced
intensity conditioning regimen in 20 patients with a median age of 63 years (range: 55–65 years)
suffering from acute leukemia (n=17) or MDS (n=3) [39]. The probability of survival was
estimated as 70% at 1 year and 52% at 2 years post-transplant. They concluded that 90Y-anti-
CD66 moAbs were more feasible and less nephrotoxic than 188Re.
Briefly, the use of RIT is an attractive approach to increase conditioning prior to HSCT. The
randomized studies in refractory aggressive or indolent NHL show the superiority of adding
RIT. Nevertheless, the addition of standard dose RIT to the conditioning regimen in autologous
transplantation is a valuable research topic. In allogeneic transplantation, until displaying the
superiority of RIT-based conditioning regimen in controlled randomized studies, this ap‐
proach should only be considered within clinical trials.
4. Alemtuzumab (Campath)
Alemtuzumab is a human originated MoAbs to CD52 that normally expresses on B and T
lymphocytes, macrophages, monocytes, natural killer cells, and some dendritic cells. While
alemtuzumab efficiently reduces both T and B cells from the circulating blood, it has minimal
or no effect on hematopoietic progenitor cells [40].
Anti-CD52 is often used in the treatment of chronic lymphocytic leukemia. But adding CD52
to the conditioning regimens in allogeneic HSCTs in many malign hematological diseases has
reduced the frequency and severity of GvHD as well as decreased the risk of graft rejection
[41-43]. Also alemtuzumab in combination with fludarabine and Cy in allogeneic HSCT for
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acquired aplastic anemia was associated with a very low incidence of chronic GvHD and
excellent survival [44-49]. However, the studies have reported that alemtuzumab led to
increase the frequency of opportunistic infection, in particular Cytomegalovirus, Epstein–Barr
virus, and Adenovirus, and the risk for the recurrence of the underlying disease due to the
reduction of graft versus tumor effects.
5. Gemtuzumab Ozogamisin
Gemtuzumab ozogamisin (GO) is a moAbs to CD33 conjugated with human calicheamicins.
It has been withdrawn from the market by the US Food and Drug Administration in 2010
because of the increasing risk of liver sinusoidal obstruction, and a lack of data for the efficacy
and safety. Recently many studies have been published about the use of GO in the treatment
of CD33+ AML patients as a part of induction therapy or consolidation [50-51]. Furthermore,
phase I/II studies have reported that the use of GO as a part of MA or RI conditioning regimens
in allo-HSCT setting could be safe and efficient in poor-risk AML patients [52-54]. In addition,
a pilot study has been recently published about the administration of GO combined with
azacytidine as the maintenance treatment of post-transplant relapses in AML [55].
6. Conclusion
Although many studies have been published for the additions of MoAbs to the conditioning
regimens for HSCTs, there are no sufficient data to determine the optimal dose and adminis‐
tration schedule of the MoAbs until now. However, rituximab recently has been widely used
in many single-arm studies in NHL patients who underwent allogeneic HSCT. Another
controversial issue is about the use of RITs. Randomized data do not support incorporating
RITs into the conditioning regimens for either autologous or allogeneic SCT settings. The high-
dose RITs should be used in refractory or advanced malign hematological disease in special‐
ized centers though lacking randomized data. The standard-dose RIT is also a good research
topic for lymphoid malignancies planning high dose therapy with autologous rescue or
allogeneic SCT.
Moreover, given the reduced risk of graft failure and GvHD with alemtuzumab but increased
risk of disease relapse and the incidence of opportunistic infections, the use of alemtuzumab
in the allogeneic SCT should be considered in patients with matched unrelated or mismatched
related donors. Owing to the shortage of studies on GO, another MoAbs, with the reuse, GO
should be used in clinical trials.
In conclusion, it is anticipated that additional MoAbs to the conditioning regimens will be
routinely used in the next door following by the proven clinical efficacy and safety.
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